{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T21:31:31Z","timestamp":1793309491766,"version":"4.5.0"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Molecular Biology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jmb.2026.170068","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T23:27:40Z","timestamp":1791934060000},"page":"170068","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Determinants of Etoposide Hypersensitivity Span All of the Top2 Alpha Catalytic Domains"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3548-5090","authenticated-orcid":false,"given":"Karin C.","family":"Nitiss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Gilbertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8180-0880","authenticated-orcid":false,"given":"Maureen N.","family":"McCoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3961-5050","authenticated-orcid":false,"given":"Abhishek","family":"Deshpande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9307-7741","authenticated-orcid":false,"given":"Anh T.Q.","family":"Cong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0952-552X","authenticated-orcid":false,"given":"Hannah","family":"Miles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viraj","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Cuaresma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7036-5943","authenticated-orcid":false,"given":"Matthew J.","family":"Schellenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1013-4972","authenticated-orcid":false,"given":"John L.","family":"Nitiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmb.2026.170068_b0005","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/s41580-022-00452-3","article-title":"Human topoisomerases and their roles in genome stability and organization","volume":"23","author":"Pommier","year":"2022","journal-title":"Nature Rev. Mol. Cell Biol."},{"key":"10.1016\/j.jmb.2026.170068_b0010","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/nrm3228","article-title":"All tangled up: how cells direct, manage and exploit topoisomerase function","volume":"12","author":"Vos","year":"2011","journal-title":"Nature Rev. Mol. Cell Biol."},{"key":"10.1016\/j.jmb.2026.170068_b0015","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nrm.2016.111","article-title":"Roles of eukaryotic topoisomerases in transcription, replication and genomic stability","volume":"17","author":"Pommier","year":"2016","journal-title":"Nature Rev. Mol. Cell Biol."},{"key":"10.1016\/j.jmb.2026.170068_b0020","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nrc2608","article-title":"DNA topoisomerase II and its growing repertoire of biological functions","volume":"9","author":"Nitiss","year":"2009","journal-title":"Nature Rev. Cancer"},{"key":"10.1016\/j.jmb.2026.170068_b0025","doi-asserted-by":"crossref","DOI":"10.1002\/bies.202000286","article-title":"DNA topoisomerases: advances in understanding of cellular roles and multi-protein complexes via structure-function analysis","volume":"43","author":"McKie","year":"2021","journal-title":"Bioessays"},{"key":"10.1016\/j.jmb.2026.170068_b0030","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1021\/cb300648v","article-title":"Drugging topoisomerases: lessons and challenges","volume":"8","author":"Pommier","year":"2013","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.jmb.2026.170068_b0035","doi-asserted-by":"crossref","first-page":"13685","DOI":"10.1073\/pnas.96.24.13685","article-title":"Topoisomerase II drives DNA transport by hydrolyzing one ATP","volume":"96","author":"Baird","year":"1999","journal-title":"PNAS"},{"key":"10.1016\/j.jmb.2026.170068_b0040","doi-asserted-by":"crossref","first-page":"6327","DOI":"10.1093\/nar\/gkr258","article-title":"The ancestral role of ATP hydrolysis in type II topoisomerases: prevention of DNA double-strand breaks","volume":"39","author":"Bates","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jmb.2026.170068_b0045","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1093\/nar\/gkad1157","article-title":"Using energy to go downhill-a genoprotective role for ATPase activity in DNA topoisomerase II","volume":"52","author":"Bandak","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jmb.2026.170068_b0050","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a025320","article-title":"Topoisomerase inhibitors: fluoroquinolone mechanisms of action and resistance","volume":"6","author":"Hooper","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.jmb.2026.170068_b0055","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1016\/j.jmb.2019.07.008","article-title":"DNA topoisomerase inhibitors: trapping a DNA-cleaving machine in motion","volume":"431","author":"Bax","year":"2019","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.jmb.2026.170068_b0060","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25235662","article-title":"Quinolones: mechanism, lethality and their contributions to antibiotic resistance","volume":"25","author":"Bush","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.jmb.2026.170068_b0065","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nrc2607","article-title":"Targeting DNA topoisomerase II in cancer chemotherapy","volume":"9","author":"Nitiss","year":"2009","journal-title":"Nature Rev. Cancer"},{"key":"10.1016\/j.jmb.2026.170068_b0070","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-biochem-030122-043917","article-title":"Structural mechanisms of topoisomerase-targeting drugs","volume":"94","author":"O'Donnell","year":"2025","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.jmb.2026.170068_b0075","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0163-7258(03)00058-5","article-title":"Catalytic topoisomerase II inhibitors in cancer therapy","volume":"99","author":"Larsen","year":"2003","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jmb.2026.170068_b0080","doi-asserted-by":"crossref","DOI":"10.1083\/jcb.202209125","article-title":"Cell cycle responses to topoisomerase II inhibition: molecular mechanisms and clinical implications","volume":"222","author":"Soliman","year":"2023","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.jmb.2026.170068_b0085","first-page":"4467","article-title":"Amsacrine and etoposide hypersensitivity of yeast cells overexpressing DNA topoisomerase II","volume":"52","author":"Nitiss","year":"1992","journal-title":"Cancer Res."},{"key":"10.1016\/j.jmb.2026.170068_b0090","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1182\/blood.V83.2.517.517","article-title":"Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia","volume":"83","author":"Kaufmann","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.jmb.2026.170068_b0095","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00997-24","article-title":"Insights into antibiotic resistance promoted by quinolone exposure","volume":"69","author":"Bush","year":"2025","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jmb.2026.170068_b0100","first-page":"4729","article-title":"Identification of a point mutation in the topoisomerase II gene from a human leukemia cell line containing an amsacrine-resistant form of topoisomerase II","volume":"51","author":"Hinds","year":"1991","journal-title":"Cancer Res."},{"key":"10.1016\/j.jmb.2026.170068_b0105","doi-asserted-by":"crossref","first-page":"7654","DOI":"10.1073\/pnas.88.17.7654","article-title":"Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide","volume":"88","author":"Bugg","year":"1991","journal-title":"PNAS"},{"key":"10.1016\/j.jmb.2026.170068_b0110","article-title":"DNA topoisomerase II mutations in cancer: structural impact and drug response in high-grade serous ovarian carcinoma","author":"Mazzoleni","year":"2025","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.jmb.2026.170068_b0115","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/S0026-895X(24)26480-4","article-title":"Mutations at arg486 and glu571 in human topoisomerase IIalpha confer resistance to amsacrine: relevance for antitumor drug resistance in human cells","volume":"57","author":"Patel","year":"2000","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.jmb.2026.170068_b0120","doi-asserted-by":"crossref","DOI":"10.3390\/ph16101456","article-title":"Prospects of topoisomerase inhibitors as promising anti-cancer agents","volume":"16","author":"Yakkala","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.jmb.2026.170068_b0125","first-page":"91","article-title":"Functional expression of human topoisomerase II alpha in yeast: mutations at amino acids 450 or 803 of topoisomerase II alpha result in enzymes that can confer resistance to anti-topoisomerase II agents","volume":"56","author":"Hsiung","year":"1996","journal-title":"Cancer Res."},{"key":"10.1016\/j.jmb.2026.170068_b0130","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1124\/mol.105.015933","article-title":"Mutation P732L in human DNA topoisomerase IIbeta abolishes DNA cleavage in the presence of calcium and confers drug resistance","volume":"69","author":"Leontiou","year":"2006","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.jmb.2026.170068_b0135","first-page":"2943","article-title":"Yeast topoisomerase II mutants resistant to anti-topoisomerase agents: identification and characterization of new yeast topoisomerase II mutants selected for resistance to etoposide","volume":"54","author":"Liu","year":"1994","journal-title":"Cancer Res."},{"key":"10.1016\/j.jmb.2026.170068_b0140","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.bbrc.2004.12.049","article-title":"Random mutagenesis of the B'A' core domain of yeast DNA topoisomerase II and large-scale screens of mutants resistant to the anticancer drug etoposide","volume":"327","author":"Jiang","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jmb.2026.170068_b0145","doi-asserted-by":"crossref","first-page":"8163","DOI":"10.1093\/nar\/gkz579","article-title":"A complex suite of loci and elements in eukaryotic type II topoisomerases determine selective sensitivity to distinct poisoning agents","volume":"47","author":"Blower","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jmb.2026.170068_b0150","doi-asserted-by":"crossref","first-page":"20943","DOI":"10.1016\/S0021-9258(17)31913-0","article-title":"Mechanistic studies of amsacrine-resistant derivatives of DNA topoisomerase II. Implications in resistance to multiple antitumor drugs targeting the enzyme","volume":"269","author":"Wasserman","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jmb.2026.170068_b0155","doi-asserted-by":"crossref","first-page":"29239","DOI":"10.1074\/jbc.M804058200","article-title":"Isolation and characterization of mAMSA-hypersensitive mutants. Cytotoxicity of Top2 covalent complexes containing DNA single strand breaks","volume":"283","author":"Rogojina","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jmb.2026.170068_b0160","doi-asserted-by":"crossref","first-page":"20359","DOI":"10.1074\/jbc.270.35.20359","article-title":"A mutation in yeast TOP2 homologous to a quinolone-resistant mutation in bacteria. Mutation of the amino acid homologous to Ser83 of Escherichia coli gyrA alters sensitivity to eukaryotic topoisomerase inhibitors","volume":"270","author":"Hsiung","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jmb.2026.170068_b0165","doi-asserted-by":"crossref","first-page":"7980","DOI":"10.1074\/jbc.275.11.7980","article-title":"A mutation in yeast topoisomerase II that confers hypersensitivity to multiple classes of topoisomerase II poisons","volume":"275","author":"Dong","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jmb.2026.170068_b0170","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2302064120","article-title":"Naturally mutagenic sequence diversity in a human type II topoisomerase","volume":"120","author":"Bandak","year":"2023","journal-title":"PNAS"},{"key":"10.1016\/j.jmb.2026.170068_b0175","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/978-1-0716-4550-5_12","article-title":"Yeast tools for studying type II topoisomerases in budding yeast","volume":"2928","author":"McCoy","year":"2025","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.jmb.2026.170068_b0180","doi-asserted-by":"crossref","first-page":"7501","DOI":"10.1073\/pnas.85.20.7501","article-title":"DNA topoisomerase-targeting antitumor drugs can be studied in yeast","volume":"85","author":"Nitiss","year":"1988","journal-title":"PNAS"},{"key":"10.1016\/j.jmb.2026.170068_b0185","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/genetics\/163.1.91","article-title":"Investigation of the stability of yeast rad52 mutant proteins uncovers post-translational and transcriptional regulation of Rad52p","volume":"163","author":"Asleson","year":"2003","journal-title":"Genetics"},{"key":"10.1016\/j.jmb.2026.170068_b0190","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/S0026-895X(24)05625-6","article-title":"Mutation E522K in human DNA topoisomerase IIbeta confers resistance to methyl N-(4'-(9-acridinylamino)-phenyl)carbamate hydrochloride and methyl N-(4'-(9-acridinylamino)-3-methoxy-phenyl) methane sulfonamide but hypersensitivity to etoposide","volume":"66","author":"Leontiou","year":"2004","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.jmb.2026.170068_b0195","doi-asserted-by":"crossref","first-page":"26876","DOI":"10.1073\/pnas.2008721117","article-title":"Trapped topoisomerase II initiates formation of de novo duplications via the nonhomologous end-joining pathway in yeast","volume":"117","author":"Stantial","year":"2020","journal-title":"PNAS"},{"key":"10.1016\/j.jmb.2026.170068_b0200","doi-asserted-by":"crossref","first-page":"28246","DOI":"10.1074\/jbc.274.40.28246","article-title":"Molecular analysis of yeast and human type II topoisomerases. Enzyme-DNA and drug interactions","volume":"274","author":"Strumberg","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jmb.2026.170068_b0205","doi-asserted-by":"crossref","first-page":"25947","DOI":"10.1074\/jbc.M312314200","article-title":"A mutation in human topoisomerase II alpha whose expression is lethal in DNA repair-deficient yeast cells","volume":"279","author":"Walker","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jmb.2026.170068_b0210","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1074\/jbc.275.3.2137","article-title":"A novel mechanism of cell killing by anti-topoisomerase II bisdioxopiperazines","volume":"275","author":"Jensen","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jmb.2026.170068_b0215","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/978-1-0716-4550-5_8","article-title":"Plasmid DNA cleavage assay with eukaryotic topoisomerase II","volume":"2928","author":"Thomas","year":"2025","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.jmb.2026.170068_b0220","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/978-1-60761-340-4_4","article-title":"Cleavage of plasmid DNA by eukaryotic topoisomerase II","volume":"582","author":"Bandele","year":"2009","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.jmb.2026.170068_b0225","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1073\/pnas.91.5.1781","article-title":"Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp","volume":"91","author":"Roca","year":"1994","journal-title":"PNAS"},{"key":"10.1016\/j.jmb.2026.170068_b0230","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1074\/jbc.275.4.2613","article-title":"Steady-state and rapid kinetic analysis of topoisomerase II trapped as the closed-clamp intermediate by ICRF-193","volume":"275","author":"Morris","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jmb.2026.170068_b0235","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJMoa035153","article-title":"The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia","volume":"351","author":"Lipshultz","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jmb.2026.170068_b0240","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3109\/10428199309148538","article-title":"Different functional states of topoisomerase II can be discriminated by orthovanadate sensitivity in multi-drug resistant human leukemic cells","volume":"9","author":"Boege","year":"1993","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.jmb.2026.170068_b0245","doi-asserted-by":"crossref","first-page":"11920","DOI":"10.1074\/jbc.M411841200","article-title":"Stability of the topoisomerase II closed clamp conformation may influence DNA-stimulated ATP hydrolysis","volume":"280","author":"Vaughn","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jmb.2026.170068_b0250","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2114024119","article-title":"Recurrent mutations in topoisomerase IIalpha cause a previously undescribed mutator phenotype in human cancers","volume":"119","author":"Boot","year":"2022","journal-title":"PNAS"},{"key":"10.1016\/j.jmb.2026.170068_b0255","doi-asserted-by":"crossref","first-page":"e4383","DOI":"10.1002\/pro.4383","article-title":"High-efficiency recombinant protein purification using mCherry and YFP nanobody affinity matrices","volume":"31","author":"Cong","year":"2022","journal-title":"Protein Sci."},{"key":"10.1016\/j.jmb.2026.170068_b0260","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/978-1-0716-4550-5_17","article-title":"Recombinant Topoisomerase 2 production using cultured human cell lines","volume":"2928","author":"Cong","year":"2025","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.jmb.2026.170068_b0265","doi-asserted-by":"crossref","first-page":"29086","DOI":"10.1074\/jbc.273.44.29086","article-title":"A mutant yeast topoisomerase II (top2G437S) with differential sensitivity to anticancer drugs in the presence and absence of ATP","volume":"273","author":"Sabourin","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jmb.2026.170068_b0270","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrd3404","article-title":"Interfacial inhibitors: targeting macromolecular complexes","volume":"11","author":"Pommier","year":"2011","journal-title":"Nature Rev. Drug Discov."},{"key":"10.1016\/j.jmb.2026.170068_b0275","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1126\/science.1204117","article-title":"Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide","volume":"333","author":"Wu","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.jmb.2026.170068_b0280","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1038\/s41467-021-23136-6","article-title":"Structural basis for allosteric regulation of human topoisomerase IIalpha","volume":"12","author":"Vanden Broeck","year":"2021","journal-title":"Nature Commun."},{"key":"10.1016\/j.jmb.2026.170068_b0285","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1074\/jbc.270.4.1913","article-title":"A yeast type II topoisomerase selected for resistance to quinolones. Mutation of histidine 1012 to tyrosine confers resistance to nonintercalative drugs but hypersensitivity to ellipticine","volume":"270","author":"Elsea","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jmb.2026.170068_b0290","doi-asserted-by":"crossref","first-page":"37041","DOI":"10.1074\/jbc.M506520200","article-title":"Nucleotide-dependent domain movement in the ATPase domain of a human type IIA DNA topoisomerase","volume":"280","author":"Wei","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jmb.2026.170068_b0295","doi-asserted-by":"crossref","first-page":"4928","DOI":"10.1038\/s41467-025-60167-9","article-title":"Topobexin targets the Topoisomerase II ATPase domain for beta isoform-selective inhibition and anthracycline cardioprotection","volume":"16","author":"Kubes","year":"2025","journal-title":"Nature Commun."},{"key":"10.1016\/j.jmb.2026.170068_b0300","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.str.2022.05.009","article-title":"A comprehensive structural analysis of the ATPase domain of human DNA topoisomerase II beta bound to AMPPNP, ADP, and the bisdioxopiperazine, ICRF193","volume":"30","author":"Ling","year":"2022","journal-title":"Structure"},{"key":"10.1016\/j.jmb.2026.170068_b0305","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jmb.2012.07.014","article-title":"The structure of DNA-bound human topoisomerase II alpha: conformational mechanisms for coordinating inter-subunit interactions with DNA cleavage","volume":"424","author":"Wendorff","year":"2012","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.jmb.2026.170068_b0310","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/yea.320070307","article-title":"Applications of high efficiency lithium acetate transformation of intact yeast cells using single-stranded nucleic acids as carrier","volume":"7","author":"Gietz","year":"1991","journal-title":"Yeast"},{"key":"10.1016\/j.jmb.2026.170068_b0315","doi-asserted-by":"crossref","DOI":"10.1101\/pdb.prot088971","article-title":"Zymolyase-treatment and polymerase chain reaction amplification from genomic and plasmid templates from yeast","volume":"2016","author":"Fuxman Bass","year":"2016","journal-title":"Cold Spring Harb. Protoc."},{"key":"10.1016\/j.jmb.2026.170068_b0320","first-page":"187","article-title":"Overexpression and purification of Saccharomyces cerevisiae DNA topoisomerase II from yeast","volume":"94","author":"Lindsley","year":"1999","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.jmb.2026.170068_b0325","doi-asserted-by":"crossref","first-page":"e250","DOI":"10.1002\/cpz1.250","article-title":"Topoisomerase assays","volume":"1","author":"Nitiss","year":"2021","journal-title":"Curr. Protoc."},{"key":"10.1016\/j.jmb.2026.170068_b0330","first-page":"57","article-title":"Use of a real-time, coupled assay to measure the ATPase activity of DNA topoisomerase II","volume":"95","author":"Lindsley","year":"2001","journal-title":"Methods Mol. Biol."}],"container-title":["Journal of Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022283626004419?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022283626004419?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:51:45Z","timestamp":1793307105000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022283626004419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":66,"alternative-id":["S0022283626004419"],"URL":"https:\/\/doi.org\/10.1016\/j.jmb.2026.170068","relation":{},"ISSN":["0022-2836"],"issn-type":[{"value":"0022-2836","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Determinants of Etoposide Hypersensitivity Span All of the Top2 Alpha Catalytic Domains","name":"articletitle","label":"Article Title"},{"value":"Journal of Molecular Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmb.2026.170068","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"170068"}}